Overall rank by patents
#34,666
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Chase Therapeutics Corporation
USPTO PatentsView assignee record - 7 granted patents across 3 technology areas, active 2020–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
7
Total patents granted
3
CPC technology areas
11.3
Avg claims per patent
-
5-year filing velocity
The verdict
Chase holds 7 US patents across 3 technology areas, rank #34,666 of 50,000 tracked assignees.
- #34,666
- of 50,000 US assignees by volume
- Top 45%
- by Innovation Score (36.7/100)
- 11.3
- avg claims per patent
Portfolio overview
Chase Therapeutics Corporation has been granted 7 US utility patents between 2020 and 2023, placing Chase Therapeutics Corporation at rank #34,666 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.3 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Chase Therapeutics Corporation is one of the more focused assignees in the PatentsView dataset. By volume, Chase sits between CHA Biotech Co., Ltd. (7 patents, rank #34,662) and Chemex Foundry Solutions Gmbh (7 patents, rank #34,670) - the closest US assignees by grant volume. The composite Innovation Score of 36.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2023, with 7 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Chase Therapeutics Corporation's 11.3 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Chase Therapeutics Corporation against peers pursuing similar technology classes.
Who files at Chase's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- CHA Biotech
CHA BIOTECH CO., LTD.
7 patents
- Chance LINE Indus…
CHANCE LINE INDUSTRIAL CO., LTD.
7 patents
- Chandler Wilkinson
CHANDLER WILKINSON, LLC
7 patents
- Changshu Tongrun…
CHANGSHU TONGRUN AUTO ACCESSORY CO., LTD
7 patents
- CHD Bioscience
CHD BIOSCIENCE, INC.
7 patents
- Chemence
CHEMENCE, INC.
7 patents
- Chemex
CHEMEX CORPORATION
7 patents
- Chemex Foundry So…
CHEMEX FOUNDRY SOLUTIONS GMBH
7 patents
- Chase Therapeutics ◀
CHASE THERAPEUTICS CORPORATION
7 patents
What this shows Chase holds 7 patents at rank #34,666, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Chase
By rank, the assignees closest to #34,666 in granted patent volume.
- CHA Biotech Co., Ltd. #34,662 · 7 patents
- Chance LINE Industrial Co., Ltd. #34,663 · 7 patents
- Chandler Wilkinson, Llc #34,664 · 7 patents
- Changshu Tongrun AUTO Accessory Co., Ltd #34,665 · 7 patents
- CHD Bioscience, Inc. #34,667 · 7 patents
- Chemence, Inc. #34,668 · 7 patents
- Chemex Corporation #34,669 · 7 patents
- Chemex Foundry Solutions Gmbh #34,670 · 7 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Chase's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Chase's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
37 Top 45% higher than 55% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 1 | 14.3% |
| 2021 | 1 | 14.3% |
| 2022 | 2 | 28.6% |
| 2023 | 3 | 42.9% |
Which technologies does Chase Therapeutics Corporation patent most?
Top 3 of 3 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Simple
Frequently Asked Questions
How many patents does Chase Therapeutics Corporation hold?
Chase Therapeutics Corporation holds 7 US granted patents filed between 2020 and 2023, spanning 3 technology areas.
What is Chase Therapeutics Corporation's Innovation Score?
Chase Therapeutics Corporation has an Innovation Score of 36.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Chase Therapeutics Corporation focus on?
Chase Therapeutics Corporation's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 7 patents. The company has filed patents in 3 CPC subclasses total.
Is Chase Therapeutics Corporation's patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Chase Therapeutics Corporation.
What does claim depth mean for Chase Therapeutics Corporation's patents?
Chase Therapeutics Corporation's patents average 11.3 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Chase Therapeutics Corporation patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Chase's 7 grants land it in the top 45% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Chase ranks #34,666 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.